Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 04:34:53 2026-06-09 am EDT			5-day change	1st Jan Change
273.75 ^DKK	+8.50%		-10.57%	-41.57%

03:47am	U.S. Futures Rise, European Stocks Mixed	DJ
Jun. 08	Major European indices flat - Zealand Pharma plunges	FW

DNB Carnegie raises Zealand Pharma price target to DKK 440 (425), reiterates Buy

Published on 05/07/2026 at 10:34 am EDT

Finwire - Translated by Marketscreener - See original

ZEALAND PHARMA A/S

+8.50%

DNB Carnegie has raised its price target for Zealand Pharma to DKK 440 from DKK 425, while maintaining its Buy rating.

Latest news about Zealand Pharma A/S

03:47am	U.S. Futures Rise, European Stocks Mixed	DJ
Jun. 08	Major European indices flat - Zealand Pharma plunges	FW
Jun. 08	Markets Ask AI for Receipts
Jun. 08	Zealand Pharma plunges following side effects in obesity drug trial	FW
Jun. 08	U.S. Futures Mixed, European Stocks Fall	DJ
Jun. 08	Zealand Pharma shares drop 25% after a quarter of patients quit obesity drug trial	RE
Jun. 08	Chips take a pounding
Jun. 08	Zealand Pharma partner reports robust Phase 3 obesity data	FW
Jun. 07	Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat	RE
Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI
Jun. 03	Deutsche Bank raises Zealand Pharma price target to DKK 300 (275), reiterates Hold	FW
Jun. 01	BNP Paribas raises Zealand Pharma price target to DKK 350 (275), reiterates Neutral - BN	FW
May. 26	Zealand Pharma A/S Elects Camilla Sylvest to the Board of Directors	CI
May. 15	U.S. Futures Down, European Stocks Fall	DJ

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.

Employees

544

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company